Bitcoin has a fixed supply limit of 21 million coins, but this scarcity does not protect it from significant price declines. The protocol reduces new supply through halving events roughly every four years, with the latest halving in April 2024 cutting mining rewards to 3.125 BTC per block. Despite these supply controls, Bitcoin has experienced price drops of 70-80% in past cycles, showing that scarcity alone doesn't guarantee price stability or growth. The next halving is expected in 2028, further reducing rewards, but it won't change the overall supply cap or eliminate market volatility.
Bitcoin's fixed supply cap of 21 million coins frames this market context. For readers following cryptocurrency markets, here is Pluang's snapshot as of Oct 17, 2026 04:51 WIB: out of 50 major cryptocurrencies, 10 rose and 39 fell today. Notable movers include SNX at Rp3.983 with a -2.88% change and 100% buy order activity, ONE at Rp27 with a -2.83% change and nearly balanced sell/buy orders, and XRP at Rp23.373 with a -2.66% change and 57% sell orders.
Changan Automobile announced new partnerships covering seven European markets and launched its "with U" service program at Mondial de l’Auto 2026. This marks a shift from market entry to building a local ecosystem including manufacturing, sales, serv...
At the 2026 Mondial de l’Auto, Changan Automobile signed letters of intent with eight companies across seven European markets and launched its "with U" service program. This marks a strategic move to build a strong local ecosystem combining manufactu...
Northland Power Inc. announced it will release its third quarter 2026 financial results after market close on November 12, 2026. The company will host an earnings call and webcast on November 13 at 9:00 a.m. ET, providing investors an opportunity to ...
Several daily leveraged ETFs tied to tech and crypto-related stocks dropped sharply, with declines over 20%. Notable falls include GraniteShares 2x Long NBIS Daily ETF down 24.5% and Leverage Shares 2x Long CRWV Daily ETF down 23.9%. These ETFs aim t...
Recent biotech IPOs Iambic Therapeutics and City Therapeutics saw significant price jumps, rising 25.9% and 22.2% respectively after their market debuts, raising substantial capital. Inverse leveraged ETFs SMCZ and SMST also gained sharply as their u...
